Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBT (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EBT for 16 consecutive years, with -$44.7 million as the latest value for Q1 2026.

  • For Q1 2026, EBT fell 564.91% year-over-year to -$44.7 million; the TTM value through Mar 2026 reached $12.1 million, down 91.09%, while the annual FY2025 figure was $66.5 million, 58.84% down from the prior year.
  • EBT hit -$44.7 million in Q1 2026 for Corcept Therapeutics, down from $9.9 million in the prior quarter.
  • Across five years, EBT topped out at $52.9 million in Q3 2024 and bottomed at -$44.7 million in Q1 2026.
  • Average EBT over 5 years is $24.9 million, with a median of $32.0 million recorded in 2024.
  • Year-over-year, EBT surged 89.83% in 2024 and then plummeted 564.91% in 2026.
  • Corcept Therapeutics' EBT stood at $24.3 million in 2022, then skyrocketed by 51.63% to $36.8 million in 2023, then fell by 13.17% to $32.0 million in 2024, then plummeted by 68.99% to $9.9 million in 2025, then crashed by 551.21% to -$44.7 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$44.7 million, $9.9 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.